Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 972 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Drug A (Blinded Drug) Clear all
Completed Phase 3 Interventional Results available

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

NCT00439244
View directory record Official record
Conditions
Osteoporosis
Interventions
Zoledronic acid, Placebo, Teriparatide
Drug
Lead sponsor
Novartis
Industry
Eligibility
45 Years to 89 Years · Female only
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • La Mesa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2011 · Synced Oct 15, 2026, 4:10 PM EDT
Recruiting Phase 2 Interventional

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

NCT07246863
View directory record Official record
Conditions
Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Interventions
Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel
Biological · Other · Drug
Lead sponsor
CatalYm GmbH
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Mineola, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 15, 2026, 4:10 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)

NCT02138825
View directory record Official record
Conditions
Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 15, 2026, 4:10 PM EDT
Completed Phase 2 Interventional Results available

Hemodynamics and Extravascular Lung Water in Acute Lung Injury

NCT00624650
View directory record Official record
Conditions
Acute Lung Injury
Interventions
Diuresis (furosemide) part I, Fluid Bolus (crystalloid or albumin), Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine), Dobutamine, Concentrate all drips and nutrition, Diuresis (furosemide) part II, Dialysis
Drug · Other · Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Clackamas, Oregon • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 15, 2026, 4:10 PM EDT
Completed Phase 2 Interventional Results available

An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants

NCT05013008
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions
Finerenone (Kerendia, BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
13
States / cities
Northridge, California • Port Hueneme, California • Waterbury, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 15, 2026, 4:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine

NCT05871541
View directory record Official record
Conditions
Herpes Zoster (HZ), Shingles, Infectious Disease
Interventions
JCXH-105, Active Control (Shingrix)
Biological
Lead sponsor
Immorna Biotherapeutics, Inc.
Industry
Eligibility
50 Years to 69 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Hollywood, Florida • Tampa, Florida • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 15, 2026, 4:10 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Ketorolac Use in Pediatric Patients Undergoing Tonsillectomy

NCT03453541
View directory record Official record
Conditions
Analgesic Adverse Reaction
Interventions
Ketorolac Tromethamine, 0.9% Normal Saline
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
2 Years to 18 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 15, 2026, 4:10 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Clinical Outcomes Related to Arthroscopic Rotator Cuff Repair Recovery Using Incrediwear

NCT06669741
View directory record Official record
Conditions
Rotator Cuff Tears, Rotator Cuff Injuries, Rotator Cuff Arthropathy of Left Shoulder (Disorder), Rotator Cuff Arthropathy of Right Shoulder (Disorder), Rotator Cuff Arthropathy of Bilateral Shoulders
Interventions
Placebo, Shoulder Sleeve
Device
Lead sponsor
Texas Bone and Joint
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Denton, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 15, 2026, 4:10 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period

NCT05175105
View directory record Official record
Conditions
Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
Interventions
Mitapivat, Mitapivat-matching placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
11
States / cities
Palo Alto, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 15, 2026, 4:10 PM EDT
Not listed Phase 2 Interventional

Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment

NCT04822961
View directory record Official record
Conditions
mCRPC
Interventions
Placebo, Senaparib
Drug
Lead sponsor
Impact Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Binghamton, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 15, 2026, 4:10 PM EDT
Recruiting Phase 3 Interventional

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

NCT07286058
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Zasocitinib
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
19
States / cities
Tucson, Arizona • Fountain Valley, California • La Mesa, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 15, 2026, 4:10 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Sleep Disruption on Drug Response

NCT03680287
View directory record Official record
Conditions
Low Back Pain, Recurrent, Healthy
Interventions
Within-Subject test of blinded study medication
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Oct 15, 2026, 4:10 PM EDT
Withdrawn Phase 4 Interventional

Particulate vs. Nonparticulate Epidural Steroid Injections for Lumbar Foraminal Stenosis

NCT03245671
View directory record Official record
Conditions
Lumbar Spinal Stenosis
Interventions
Kenalog Injectable Product, Decadron Phosphate, Injectable, Epidural Steroid Injection
Drug · Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 15, 2026, 4:10 PM EDT
Completed Phase 4 Interventional

Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients

NCT00870311
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 27, 2009 · Synced Oct 15, 2026, 4:10 PM EDT
Terminated No phase listed Observational

Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix)

NCT01532232
View directory record Official record
Conditions
Breast Cancer, Tobacco Dependence
Interventions
placebo, varenicline
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 15, 2026, 4:10 PM EDT
Completed Phase 4 Interventional Results available

Placebo In Chronic Back Pain - Double-Blind Randomized Control Trial

NCT02013427
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Naproxen, Placebo, Omeprazole
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 15, 2026, 4:10 PM EDT
Terminated Phase 2 Interventional Results available

Effects of Liposomal Bupivacaine for Acute Pain in Hip and Femur Fractures

NCT02679560
View directory record Official record
Conditions
Femoral Fractures
Interventions
Liposomal Bupivacaine, Ropivacaine HCL
Drug
Lead sponsor
Ian Elliott Brown
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 15, 2026, 4:10 PM EDT
Completed Not applicable Interventional Results available

Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant

NCT01759862
View directory record Official record
Conditions
Function of Renal Transplant
Interventions
Aminophylline, Theophylline drug levels, Placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 15, 2026, 4:10 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effect of Near-infrared Light Therapy on Brain Function and Cognition in Young and Older Adults

NCT07209683
View directory record Official record
Conditions
Cognition, Neurovascular Coupling Mechanism and Cognitive Function, Neurovascular Control, Brain Aging, Brain Activity
Interventions
transcranial photobiomodulation
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
21 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 15, 2026, 4:10 PM EDT
Recruiting Phase 4 Interventional

Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes

NCT05780905
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Stroke (CVA) or Transient Ischemic Attack
Interventions
Semaglutide Auto-Injector, Placebo
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
40 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 15, 2026, 4:10 PM EDT
Suspended Phase 2Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of PEER Interactive to Inform Medication Prescription for Subjects With a Primary Diagnosis of Depression

NCT02988076
View directory record Official record
Conditions
Depression
Interventions
PEER Interactive Report
Device
Lead sponsor
MYnd Analytics
Industry
Eligibility
18 Years to 65 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 15, 2026, 4:10 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

NCT02065570
View directory record Official record
Conditions
Crohn's Disease
Interventions
Adalimumab, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
48
States / cities
Birmingham, Alabama • Dothan, Alabama • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 15, 2026, 4:10 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer

NCT00730158
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
KD018, Irinotecan, Placebo
Drug
Lead sponsor
Edward Chu, MD
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
New Haven, Connecticut • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Oct 15, 2026, 4:10 PM EDT
Recruiting Phase 3 Interventional

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

NCT07623161
View directory record Official record
Conditions
Myelofibrosis, Anemia
Interventions
Placebo, Elritercept
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
30
States / cities
Gilbert, Arizona • Glendale, California • Whittier, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 4:10 PM EDT